Oxiquim Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Oxiquim.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Chemicals winstgroei	56.2%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Returns At Oxiquim (SNSE:OXIQUIM) Appear To Be Weighed Down

May 25

Oxiquim's (SNSE:OXIQUIM) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 07

Oxiquim S.A.'s (SNSE:OXIQUIM) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 11

Is Oxiquim (SNSE:OXIQUIM) Using Too Much Debt?

Feb 18

Did You Participate In Any Of Oxiquim's (SNSE:OXIQUIM) Incredible 355% Return?

Jan 27

Has Oxiquim (SNSE:OXIQUIM) Got What It Takes To Become A Multi-Bagger?

Dec 28

Oxiquim S.A. (SNSE:OXIQUIM) On An Uptrend: Could Fundamentals Be Driving The Stock?

Dec 07

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Oxiquim onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SNSE:OXIQUIM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CLP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	219,232	25,302	28,321	40,192	N/A
3/31/2024	216,232	23,655	27,083	38,950	N/A
12/31/2023	214,649	23,896	27,739	40,573	N/A
9/30/2023	221,904	24,930	28,077	42,743	N/A
6/30/2023	243,733	27,088	22,016	36,393	N/A
3/31/2023	258,547	27,220	8,425	23,340	N/A
12/31/2022	264,695	29,252	3,446	15,979	N/A
9/30/2022	262,663	28,624	7,175	19,119	N/A
6/30/2022	238,874	25,710	1,578	11,795	N/A
3/31/2022	213,134	24,850	9,036	19,582	N/A
12/31/2021	191,128	20,727	10,523	21,859	N/A
9/30/2021	170,947	18,471	7,701	23,493	N/A
6/30/2021	161,252	18,276	11,142	30,618	N/A
3/31/2021	155,708	16,972	11,105	30,697	N/A
12/31/2020	158,135	17,219	11,656	33,299	N/A
9/30/2020	158,113	16,720	6,499	28,481	N/A
6/30/2020	155,569	15,368	2,271	22,177	N/A
3/31/2020	155,075	15,874	11,003	28,813	N/A
12/31/2019	152,021	15,618	12,255	27,042	N/A
9/30/2019	154,655	14,770	10,891	20,820	N/A
6/30/2019	157,881	16,018	18,888	28,597	N/A
3/31/2019	158,870	15,263	6,889	16,451	N/A
12/31/2018	156,502	14,302	9,405	18,635	N/A
9/30/2018	151,351	13,534	14,705	21,781	N/A
6/30/2018	146,847	12,685	12,304	17,028	N/A
3/31/2018	145,208	18,055	N/A	29,839	N/A
12/31/2017	144,253	18,294	N/A	25,760	N/A
9/30/2017	141,722	21,842	N/A	24,332	N/A
6/30/2017	138,877	21,562	N/A	24,845	N/A
3/31/2017	135,566	16,033	N/A	22,466	N/A
12/31/2016	134,438	16,492	N/A	23,811	N/A
9/30/2016	136,729	13,242	N/A	26,257	N/A
6/30/2016	140,238	13,054	N/A	23,287	N/A
3/31/2016	142,591	12,493	N/A	23,350	N/A
12/31/2015	144,059	12,013	N/A	21,237	N/A
9/30/2015	144,708	10,554	N/A	28,647	N/A
6/30/2015	142,750	9,386	N/A	26,275	N/A
3/31/2015	140,734	9,598	N/A	17,258	N/A
12/31/2014	140,119	8,592	N/A	21,385	N/A
9/30/2014	128,174	8,715	N/A	-4,186	N/A
6/30/2014	129,377	7,667	N/A	4,921	N/A
3/31/2014	134,570	6,195	N/A	6,617	N/A
12/31/2013	133,314	5,392	N/A	-562	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if OXIQUIM's forecast earnings growth is above the savings rate (5.5%).

Winst versus markt: Insufficient data to determine if OXIQUIM's earnings are forecast to grow faster than the CL market

Hoge groeiwinsten: Insufficient data to determine if OXIQUIM's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if OXIQUIM's revenue is forecast to grow faster than the CL market.

Hoge groei-inkomsten: Insufficient data to determine if OXIQUIM's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if OXIQUIM's Return on Equity is forecast to be high in 3 years time

Oxiquim Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Upcoming dividend of CL$362 per share

Second quarter 2024 earnings released: EPS: CL$295 (vs CL$229 in 2Q 2023)

First quarter 2024 earnings released: EPS: CL$234 (vs CL$244 in 1Q 2023)

Returns At Oxiquim (SNSE:OXIQUIM) Appear To Be Weighed Down

Upcoming dividend of CL$282 per share

New minor risk - Financial position

Full year 2023 earnings released: EPS: CL$960 (vs CL$1,175 in FY 2022)

New minor risk - Financial position

Upcoming dividend of CL$60.00 per share at 10% yield

Third quarter 2023 earnings released: EPS: CL$222 (vs CL$308 in 3Q 2022)

Upcoming dividend of CL$402 per share at 13% yield

Second quarter 2023 earnings released: EPS: CL$229 (vs CL$235 in 2Q 2022)

Upcoming dividend of CL$201 per share at 13% yield

New minor risk - Financial position

First quarter 2023 earnings released: EPS: CL$0.24 (vs CL$326 in 1Q 2022)

Oxiquim's (SNSE:OXIQUIM) Shareholders May Want To Dig Deeper Than Statutory Profit

Full year 2022 earnings released: EPS: CL$1,175 (vs CL$834 in FY 2021)

Third quarter 2022 earnings released: EPS: CL$309 (vs CL$192 in 3Q 2021)

No independent directors

Upcoming dividend of CL$282 per share

Second quarter 2022 earnings released

Upcoming dividend of CL$321 per share

First quarter 2022 earnings released: EPS: CL$326 (vs CL$160 in 1Q 2021)

No independent directors

Full year 2021 earnings released: EPS: CL$834 (vs CL$692 in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of CL$322 per share

Second quarter 2021 earnings released: EPS CL$200 (vs CL$147 in 2Q 2020)

Upcoming dividend of CL$160 per share

Is Oxiquim (SNSE:OXIQUIM) Using Too Much Debt?

First quarter 2021 earnings released: EPS CL$160 (vs CL$170 in 1Q 2020)

Upcoming dividend of CL$120 per share

Are Dividend Investors Making A Mistake With Oxiquim S.A. (SNSE:OXIQUIM)?

Returns At Oxiquim (SNSE:OXIQUIM) Appear To Be Weighed Down

Full year 2020 earnings released: EPS CL$692 (vs CL$628 in FY 2019)

Oxiquim S.A.'s (SNSE:OXIQUIM) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Is Oxiquim (SNSE:OXIQUIM) Using Too Much Debt?

Did You Participate In Any Of Oxiquim's (SNSE:OXIQUIM) Incredible 355% Return?

New 90-day high: CL$6,025

New 90-day high: CL$5,500

Has Oxiquim (SNSE:OXIQUIM) Got What It Takes To Become A Multi-Bagger?

Oxiquim S.A. (SNSE:OXIQUIM) On An Uptrend: Could Fundamentals Be Driving The Stock?

Third quarter 2020 earnings released: EPS CL$184

Upcoming Dividend of CL$200 Per Share

New 90-day high: CL$5,200

First half earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven